千金藤素 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "千金藤素" in Chinese language version.

refsWebsite

Global rank Chinese rank

8web.archive.org

1^st place

3nih.gov

4^th place

5^th place

2doi.org

2^nd place

23^rd place

2sina.com.cn

144^th place

3^rd place

1wikipedia.org

low place

1semanticscholar.org

11^th place

332^nd place

1iiarjournals.org

low place

1if-pan.krakow.pl

low place

1jwview.com

low place

2,618^th place

1stdaily.com

low place

2,951^st place

1ce.cn

2,250^th place

78^th place

1eastmoney.com

low place

960^th place

1patents.google.com

1,182^nd place

2,253^rd place

ce.cn

火上热搜的千金藤素，是“新冠神药”还是“空头支票”. 中国经济网. 2022-05-19 [2022-06-03]. （原始内容存档于2022-06-03）.

doi.org

Huang H, Hu G, Wang C, Xu H, Chen X, Qian A. Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models. Inflammation. February 2014, 37 (1): 235–46. PMID 24045962. S2CID 7186762. doi:10.1007/s10753-013-9734-8.
Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions (PDF). Pharmacological Reports. 2011, 63 (2): 337–47 [2022-06-03]. PMID 21602589. doi:10.1016/S1734-1140(11)70500-X. （原始内容 (PDF)存档于2021-07-01）.

eastmoney.com

finance.eastmoney.com

“千金藤素”能治新冠？概念股暴涨多家药企紧急澄清. 东方财富网. 2022-05-19 [2022-06-03]. （原始内容存档于2022-05-18）.

if-pan.krakow.pl

Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions (PDF). Pharmacological Reports. 2011, 63 (2): 337–47 [2022-06-03]. PMID 21602589. doi:10.1016/S1734-1140(11)70500-X. （原始内容 (PDF)存档于2021-07-01）.

iiarjournals.org

ar.iiarjournals.org

Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, Baba M. Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative. Anticancer Research. July 2012, 32 (7): 2639–45 [2022-06-03]. PMID 22753721. （原始内容存档于2021-06-30）.

jwview.com

千金藤素降温！“新冠奇药”两年没开展临床试验，因为没钱？. 中新经纬. 2022-05-17 [2022-06-03].

nih.gov

ncbi.nlm.nih.gov

Huang H, Hu G, Wang C, Xu H, Chen X, Qian A. Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models. Inflammation. February 2014, 37 (1): 235–46. PMID 24045962. S2CID 7186762. doi:10.1007/s10753-013-9734-8.
Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, Baba M. Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative. Anticancer Research. July 2012, 32 (7): 2639–45 [2022-06-03]. PMID 22753721. （原始内容存档于2021-06-30）.
Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions (PDF). Pharmacological Reports. 2011, 63 (2): 337–47 [2022-06-03]. PMID 21602589. doi:10.1016/S1734-1140(11)70500-X. （原始内容 (PDF)存档于2021-07-01）.

patents.google.com

千金藤素在制备抗sars病毒药物中的应用. Google Patents. 2005-05-18 [2022-06-03]. （原始内容存档于2022-06-03）（中文（中国大陆））.

semanticscholar.org

api.semanticscholar.org

Huang H, Hu G, Wang C, Xu H, Chen X, Qian A. Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models. Inflammation. February 2014, 37 (1): 235–46. PMID 24045962. S2CID 7186762. doi:10.1007/s10753-013-9734-8.

sina.com.cn

finance.sina.com.cn

疯炒！“千金藤素”能治新冠？概念股暴涨，华北制药、千金药业多家药企紧急澄清…. 新浪财经. 2022-05-18 [2022-06-03]. （原始内容存档于2022-06-03）.
生物谷实控人被立案调查！“千金藤素抗新冠”争议背后难题：外界质疑无临床证据，研发团队说没钱没资源. 新浪财经. 2022-05-25 [2022-06-03]. （原始内容存档于2022-06-03）.

stdaily.com

我科学家发现新冠治疗新药并获发明专利授权. 中国科技网. 2022-05-13 [2022-06-03]. （原始内容存档于2022-05-18）.

web.archive.org

Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, Baba M. Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative. Anticancer Research. July 2012, 32 (7): 2639–45 [2022-06-03]. PMID 22753721. （原始内容存档于2021-06-30）.
Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions (PDF). Pharmacological Reports. 2011, 63 (2): 337–47 [2022-06-03]. PMID 21602589. doi:10.1016/S1734-1140(11)70500-X. （原始内容 (PDF)存档于2021-07-01）.
我科学家发现新冠治疗新药并获发明专利授权. 中国科技网. 2022-05-13 [2022-06-03]. （原始内容存档于2022-05-18）.
火上热搜的千金藤素，是“新冠神药”还是“空头支票”. 中国经济网. 2022-05-19 [2022-06-03]. （原始内容存档于2022-06-03）.
疯炒！“千金藤素”能治新冠？概念股暴涨，华北制药、千金药业多家药企紧急澄清…. 新浪财经. 2022-05-18 [2022-06-03]. （原始内容存档于2022-06-03）.
“千金藤素”能治新冠？概念股暴涨多家药企紧急澄清. 东方财富网. 2022-05-19 [2022-06-03]. （原始内容存档于2022-05-18）.
生物谷实控人被立案调查！“千金藤素抗新冠”争议背后难题：外界质疑无临床证据，研发团队说没钱没资源. 新浪财经. 2022-05-25 [2022-06-03]. （原始内容存档于2022-06-03）.
千金藤素在制备抗sars病毒药物中的应用. Google Patents. 2005-05-18 [2022-06-03]. （原始内容存档于2022-06-03）（中文（中国大陆））.

wikipedia.org

en.wikipedia.org

据山东大学齐鲁医院临床药理中心郭瑞臣教授介绍，金藤素为多种千金藤生物碱的混合成分，用摩尔表示是不准确的；另外，15393倍在药学中应用ED50（英语：Effective dose (pharmacology)）（半有效量）表示^[4]。